



mRNA Therapeutics for Cancer Treatment

Guest Editors:

Dr. Fatemeh Movahedi

Australian Institute for
Bioengineering and
Nanotechnology, The University
of Queensland, Brisbane, QLD
4067, Australia

Prof. Dr. Chengzhong Yu

Australian Institute for
Bioengineering and
Nanotechnology, The University
of Queensland, Brisbane, QLD
4072, Australia

Deadline for manuscript
submissions:

20 June 2024

Message from the Guest Editors

Our Special Issue seeks original research articles and reviews that delve into various aspects of mRNA therapeutics for cancer, including but not limited to:

- mRNA-based cancer vaccines: explore the development and mechanisms of personalized mRNA vaccines tailored to individual tumor profiles, and their potential to induce targeted immune responses against cancer cells;
- Clinical insights: share the latest findings from clinical trials and studies evaluating the efficacy and safety of mRNA-based cancer therapies, shedding light on their real-world applications;
- Synergy with existing treatments: investigate the potential synergy between mRNA therapies and other established cancer treatment modalities, such as immunotherapy and targeted therapies, to maximize patient outcomes;
- Innovations in delivery: highlight advancements in mRNA delivery technologies, including lipid nanoparticles and other innovative approaches, that enhance the precision and effectiveness of cancer therapeutics;
- Future directions: discuss the future directions and challenges in the field of mRNA therapeutics for cancer treatment, identifying promising avenues for further research.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma